Financials
Financial year 2025
PHARMADIX from Wevelgem, company number BE0794868478, closed financial year 2025 with a result of € 62,389 after tax. For that financial year PHARMADIX recorded a gross margin of € 82,674 and equity of € 203,726. Compared with financial year 2024, the result moved from € 38,317 to € 62,389. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 22, 2026.
€ 203,726
▲ 44% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 62,389
▲ 63% vs 2024
Profit after tax over the fiscal year.
€ 65,397
▼ 34% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 193,726.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 15,800
▼ 10% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 5,202
▼ 80% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|
| Gross margin | € 133,898 | € 60,907 | € 82,674 | ▲ 36% |
| Profit after taxes | € 93,020 | € 38,317 | € 62,389 | ▲ 63% |
| Equity | € 103,020 | € 141,337 | € 203,726 | ▲ 44% |
| Total debts | € 27,325 | € 45,581 | € 21,743 | ▼ 52% |
| Cash | € 56,841 | € 99,380 | € 65,397 | ▼ 34% |
| Retained profit | € 93,020 | € 131,337 | € 193,726 | ▲ 48% |
| Bank debt | € 0 | € 1,714 | € 0 | ▼ 100% |
| Balance sheet total | € 130,345 | € 186,918 | € 225,469 | ▲ 21% |
Key figures of PHARMADIX, fiscal years 2023 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
Ask about PHARMADIX the way you would ask their accountant.
Answers from the filed annual accounts, the Belgian Official Gazette and the CBE register.
Connect ChatGPT or Claude for free- ChatGPT
- Claude
Free account, no payment card. Key figures unlimited, the annual accounts and deeds of 10 companies a month. Need more? Get in touch, we are looking for our first pilot users.
What happened to PHARMADIX?
What happened at PHARMADIX in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 62,389 (▲ 63% vs 2024). Source: NBB ↗
- Incorporation, published in the Gazette. Source: Staatsblad ↗
- New establishment in Wevelgem. KBO
- Dirk Vanneste became a director. NBB
- Anne Marie Lozie became a director. NBB
In short
From € 93,020 profit in 2023 to € 62,389 profit in 2025.
Paid € 75,795 in corporate taxes since 2023.
Best year ever: 2023, with € 93,020 profit.
Management
Behind PHARMADIX are Dirk Vanneste and Anne Marie Lozie.
Directors
According to the 2025 annual accounts
Dirk Vanneste
Director
since 2022
Anne Marie Lozie
Director
since 2022
Establishments
Establishment units
Physical locations of this company
Korteweg 5
8560 Wevelgem
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Shareholders according to the Official Gazette deeds
Who contributed at incorporation and at capital increases, with the deed as source. Later share transfers are not published in the Gazette.
Incorporation
Source: Deed ↗- VANNESTE Dirk Jozef Maria(oprichter) 50%
- LOZIE Anne Marie Louise Yvonne Delphine(oprichter) 50%
Details
- Company number
- 0794.868.478
- VAT number
- BE 0794.868.478
- Registered office
- Korteweg 5, 8560 Wevelgem
- Names & denominations
- PHARMADIX
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 16 December 2022
- Peppol
- Active · Active since 28 Feb 2025
- Activities · NACE
Overige detailhandel in voedingsmiddelen, neg
Overige detailhandel in voedingsmiddelen in gespecialiseerde winkels, n.e.g.